Global Flow Cytometry Market - Global Forecast to 2027

The flow cytometry market is predicted to grow by 8.1 percent per year from USD 4.3 billion in 2021 to USD 6.3 billion in 2027. The rising global incidence and prevalence of HIV/AIDS and cancer, growing adoption of flow cytometry techniques in research and academia, growing public-private initiatives in the fields of immunology and immuno-oncology research, technological advancements, and the increasing incorporation of AI platforms in flow cytometry workflows, and advancements in flow cytometry software are all driving the growth of the flow cytometry market.

Impact of COVID-19 on the Global Flow Cytometry Market

COVID-19 is an infectious disease caused by a novel Coronavirus that was recently discovered. COVID-19, which was mostly unknown before the outbreak in Wuhan, China, in December 2019, has evolved from a regional issue to a global pandemic. The outbreak of COVID-19 has been declared a pandemic by the World Health Organization (WHO). Countries have implemented a variety of measures to combat the disease's spread, including stringent travel restrictions, city-wide quarantines, curfews, and lockdowns, the creation of speciality hospitals, more medical aid, and increased COVID-19 testing. It's a worrying situation since countries that thought they'd stopped the virus from spreading are now dealing with a second wave of the COVID-19 pandemic, which is driving up demand for a COVID-19 vaccine around the world.

The COVID-19 pandemic prompted researchers all across the world to respond. Flow cytometry has been utilised in several research to look at how the immune system reacts to SARS-CoV-2. For example, researchers discovered that COVID-19 patients had lower B-cell and T-cell frequencies than recovered donors and healthy donors using flow cytometry.

Another study used a flow-cytometric bead array (C19BA) to assess seroconversion against SARS-CoV-2, taking advantage of the technology's multiplex capability to examine the existence of IgG and IgM antibodies against three viral antigens at the same time. The presence of N-reactive antibodies in a cohort of samples collected before to the pandemic was discovered using this method, demonstrating that cross-reactivity against this conserved viral protein existed.